Search results for: 'due+cultur+scienc+2025'

Global Academic and Non-Profit Partnering Terms and Agreements 2019-2025 report provides a detailed understanding and analysis of how and why companies enter Academic and Non-Profit partnering deals. 

Distribution Deals in Diagnostics | Global coverage | Deal financials | Contract documents | Deal trends | Leading dealmakers | Comprehensive deal directory 2016 to 2025

Distribution Deals in Medical Devices | Global coverage | Deal financials | Contract documents | Deal trends | Leading dealmakers | Comprehensive deal directory 2016 to 2025

Biomarker Collaboration and Licensing Deals | Global coverage | Deal financials | Contract documents | Deal trends | Leading dealmakers | Collaboration, licensing, development, and research deals |Comprehensive deal directory 2016 to 2025

Genomics Collaboration and Licensing Deals | Global coverage | Deal financials | Contract documents | Deal trends | Leading dealmakers | Collaboration, licensing, development, and research deals |Comprehensive deal directory 2018 to 2025

Autoimmune Collaboration and Licensing Deals | Global coverage | Deal financials | Contract documents | Deal trends | Leading dealmakers | Collaboration, licensing, development, and research deals |Comprehensive deal directory 2016 to 2025

Dermatology Collaboration and Licensing Deals | Global coverage | Deal financials | Contract documents | Deal trends | Leading dealmakers | Collaboration, licensing, development, and research deals |Comprehensive deal directory 2016 to 2025

Distribution Deals in Pharmaceuticals and Biotechnology | Global coverage | Deal financials | Contract documents | Deal trends | Leading dealmakers | Comprehensive deal directory 2020 to 2025

Antibody Collaboration and Licensing Deals | Global coverage | Deal financials | Contract documents | Deal trends | Leading dealmakers | Collaboration, licensing, development, and research deals |Comprehensive deal directory 2019 to 2025

Analyze co-development deals in pharma and biotech from 2016 to 2025. Includes financials, deal terms, and access to actual contracts where available.